
    
      -  Study institutions: Four university hospitals in Korea

        -  Design: Multi-center, randomized, placebo-controlled, double-blind clinical trial

        -  Subjects: 74 probable Alzheimer's disease patients who have been taking donepezil at
           stable dose within 2 months (Escitalopram 37 : Placebo 37)
    
  